Presentations by Program

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Rana K, Wunderink R, Tsuei B, Rahav G, Kovalchuk E, Koksal I, Maloney K and Srinivasan S (IDWeek 2020)

Sulbactam-Durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

McLeod S, Moussa S, Hackel M, and Miller A (IDWeek 2020)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug Resistant (MDR) Mycobacterium abscessus (Mab)

Dousa KM, Kurz SG, Bethel CR, Taracilla M, Miller AA and Bonomo RA (IDWeek 2020)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

In Vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

McLeod SM, Mathur T, Hackel M, Wise M, Morrissey I and Miller AA (IDWeek 2019)

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Miller AA, O'Donnell JP, Lane DJ, Panchal RG and Mueller JP (IDWeek 2019)

Resistance to Sulbactam-Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Moussa S, Shapiro AB, McLeod SM and Miller AA (Acinetobacter 2019)

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

O'Donnell J (Microbe 2019)

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Huband M, Edah Y, Tommasi R and Miller A (Microbe 2019)

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)